Search Results
CAR-T Immunotherapy Showing Positive Results
This week, positive data from a Kite Pharma CAR-T immunotherapy clinical trial was released showing that more than one-third of refractory aggressive non-Hodgkin lymphoma (NHL) patients in the study showed no signs of the disease after six months.
Since 2015, The Leukemia & Lymphoma Society has been funding this study through its collaboration with Kite Pharma, a biotechnology company focused on immunotherapy.
Stopping Gleevec to Start a Family
Erin Zammett Ruddy is a magazine journalist and blogger who was diagnosed with chronic myeloid leukemia at age 23. Today, she is a 40-year-old mother of three.
On January 30 I turned 40. The big 4-0! My grandma Adele and I shared a birthday, and she’d be aghast if she knew I was telling all of you my real age right now. Grandma Del was a Radio City Rockette and very glamorous—and she never turned a day over 29, despite living to 85 (sorry, Grandma). But I am damn proud of being 40, newly-formed wrinkles and all.
LLS Activates to Accelerate Cures
The Leukemia & Lymphoma Society (LLS) continually advocates for laws and policies to ensure that patients have access to lifesaving treatments. Our latest win came this summer when the U.S. House of Representatives approved the 21st Century Cures Act.
This bill, which is proof of LLS’s impact and would make a big difference for blood cancer patients, is now on Congress’ “to do” list.
LLS Partner Advances Promising Therapy for Rare Leukemia
A potential new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a very rare form of blood cancer with no standard treatment, continues to show promise as it moves through early clinical trials. The Leukemia & Lymphoma Society (LLS) has a long history of supporting the development of SL-401, a targeted therapy that has shown significant anti-tumor effects.
#ASH18: The Beat Goes On
On Sunday, I reported on a press briefing at the 60th ASH Annual Meeting where the preliminary findings of our Beat AML Master Clinical Trial were unveiled. This innovative collaborative study is designed to bring the hope of precision medicine to patients with acute myeloid leukemia (AML). (Read about our Friday ASH satellite symposium on immunotherapy here).
World-Renowned Chef & Cancer Survivor Cooks for a Cure
Shortly before Steve McHugh and his wife moved to San Antonio in 2010, the rising star chef was diagnosed with non-Hodgkin lymphoma and spent a year undergoing eight rounds of chemotherapy.
“Chemotherapy was a real roller coaster – I experienced insomnia, constipation and dizzy spells. There were times I would not sleep for three to four days,” he said.
How Surviving Cancer Gave me a Second Birthday
Birthdays are a time for celebration as we become one year older, wiser, and more mature. For cancer survivors, we carry with us another date that symbolizes even more. This is our second birthday. Similar to an actual birthday, this day often carries feelings of even more nostalgia and remembrance. However, it can also grip us with feelings of dread, anxiety, and even post-traumatic stress disorder (PTSD). No matter how far along we are in our journey through survivorship, our second birthday pulls at us to stop and compassionately remember all that we’ve been through.
Dispelling Misunderstandings About Clinical Trials
As a clinical trials specialist for The Leukemia & Lymphoma Society, I guide blood cancer patients and their families through the process of determining whether a clinical trial might be right for them. I try to clarify any misconceptions people have about what is involved so they will be in a much better place to make a decision. This blog addresses some of the most common misunderstandings. Considering a clinical trial for treatment of a blood cancer?
Why Monthly Giving Matters
Giving regularly over time = giving patients and survivors the chance for more time.
Monthly giving really deserves more credit—credit as a predictable, impactful funding force for our lifesaving and life-changing work. For The Leukemia & Lymphoma Society (LLS), the reliability of a regular gift helps to sustain cutting-edge research and to provide the free resources and support blood cancer patients and survivors need to live longer, better lives.
It’s about ongoing generosity. It’s about creating a lasting impact.
And...
DEVELOPING RELATIONSHIPS ON CAPITOL HILL
As the voice for all blood cancer patients, The Leukemia & Lymphoma Society (LLS) establishes and grows meaningful relationships with policymakers
The Leukemia & Lymphoma Society is committed to removing barriers to care for blood cancer patients, and works with federal and state legislators to advocate for policies to ensure patients have access to quality, affordable care and treatments they need.
Here’s an inside look at how we cultivate these key connections:
Understanding Myeloma: A Quick Guide
Myeloma is a rare blood cancer
A New CAR-T Approval Brings Hope for Mantle Cell Lymphoma Patients
The U.S. Food and Drug Administration (FDA) today announced its approval for a breakthrough treatment that will bring the promise of immunotherapy and new hope to thousands of patients diagnosed with mantle cell lymphoma (MCL) whose previous treatments fail to bring them lasting remissions.
BRIDGE (Blood cancer Research Initiative Developing Greater Engagement) with community patients
The Weill Cornell Medicine (WCM) Meyer Cancer Center (MCC) has an internationally recognized, clinical/translational blood cancer research program focused at its Manhattan campus. Elsewhere in New York City, the borough of Queens has 2.3 million and the borough of Brooklyn has 2.5 million residents. Both are among the most ethnically diverse urban areas in the world, and each separately ranks just behind Los Angeles and Chicago in population. Over 50% of patients diagnosed with blood cancers in New York City live in Brooklyn or Queens, and half of those are non-white.Another Option Available for Multiple Myeloma Patients
Just on the heels of two approvals last week, the FDA today approved a third therapy to treat patients with multiple myeloma. Elotuzumab (Emplicity ™) is approved for use in combination with another drug, lenalidomide (Revlimid ®) for patients who have failed previous therapies.
Ifosfamide
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Every Year Counts: Celebrating My Healing from Hodgkin Lymphoma
Many blood cancer survivors remember the day they were diagnosed, and they never forget it. For Racheli Alkobey Peltier—Director of Diversity, Equity, and Inclusion at The Leukemia & Lymphoma Society (LLS)— when that date comes around, it’s a chance to mark her progress.
Each year, Racheli marks important milestones in her experience with blood cancer—taking time to reflect, feel gratitude, and look ahead. These dates are her “cancerversaries.”
Looking Ahead to 2016
LLS CEO and President Louis J. DeGennaro speaks out about coming off a “phenomenal” year and what we can look forward to in 2016. He shares his optimism about a future with no chemotherapy, the use of the word “cure,” the increasing promise of immunotherapy, and the potential of having hundreds of compounds in development.
Six top topics that will be important for blood cancer patients and families:
Curing AML in Elderly Patients
Robert Hromas, M.D., a blood cancer expert at the University of Florida's College of Medicine, is looking to discover new drugs that will improve the response of elderly AML patients to chemotherapy. His latest research, funded through a Translational Research Program grant from The Leukemia & Lymphoma Society, focuses on inhibiting the DNA repair response.
My Myeloma Story
“What is multiple myeloma?” Those were my words after the doctor’s review of my lab results for a routine and random high blood pressure exam in November 2008.
Striving for Social Justice, Racial Equality and Diversity
As a patient focused organization, we stand for:
- All cancer patients, working to ensure they have access to quality affordable care.
- Racial justice and equality for Black people.
- Diversity and inclusion among our staff and volunteers.
We stand against hate, prejudice and injustice.